188 related articles for article (PubMed ID: 32631434)
1. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience.
Wang L; Zhu H; Zhao Y; Pan Q; Mao A; Zhu W; Zhang N; Lin Z; Zhou J; Wang Y; Zhang Y; Wang M; Feng Y; He X; Xu W; Wang L
J Transl Med; 2020 Jul; 18(1):273. PubMed ID: 32631434
[TBL] [Abstract][Full Text] [Related]
2. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
4. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
5. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
6. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
Zhang C; You X; Zhang Q; Wang D
Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
[TBL] [Abstract][Full Text] [Related]
8. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W; Laurent-Puig P; Ziol M; Ganne-Carrié N; Nahon P; Ait-Omar A; Seror O; Sidali S; Campani C; Blanc P; Lermine A; Marisa L; Zucman-Rossi J; Nault JC
J Hepatol; 2023 Dec; 79(6):1450-1458. PubMed ID: 37647991
[TBL] [Abstract][Full Text] [Related]
9. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study.
Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679
[TBL] [Abstract][Full Text] [Related]
12. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M; Macarulla T; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Nappo F; Nichetti F; Lai E; Valgiusti M; Cappetta A; Febregat C; Fassan M; De Braud F; Puzzoni M; Frassineti GL; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Eur J Cancer; 2022 Aug; 171():232-241. PubMed ID: 35749808
[TBL] [Abstract][Full Text] [Related]
13. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
14. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.
Yu Y; Liu Q; Li W; Qu Y; Zhang Y; Liu T
Oncologist; 2020 Dec; 25(12):1005-1008. PubMed ID: 32897609
[TBL] [Abstract][Full Text] [Related]
16. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.
Ahn KS; O'Brien D; Kang YN; Mounajjed T; Kim YH; Kim TS; Kocher JA; Allotey LK; Borad MJ; Roberts LR; Kang KJ
Hepatol Int; 2019 Jul; 13(4):490-500. PubMed ID: 31214875
[TBL] [Abstract][Full Text] [Related]
17. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Clinical Use of Molecular Profiling of Intrahepatic Cholangiocarcinoma in a Comprehensive Multidisciplinary Clinic.
Purchla J; Ghabi EM; Burns WR; Lafaro KJ; Burkhart RA; Cameron JL; Yarchoan M; Shubert CR; Baretti M; He J
J Am Coll Surg; 2024 Apr; 238(4):532-540. PubMed ID: 38189646
[TBL] [Abstract][Full Text] [Related]
19. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.
Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS
J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
